Targeting CD38 with isatuximab and a novel CD38/CD3xCD28 trispecific T-cell engager in older patients with acute myeloid leukemia

被引：4

作者：

Martin-Sanchez, Esperanza ^{[1
]}

Blanco, Laura ^{[1
]}

Kim, Peter S. ^{[2
]}

Bisht, Kamlesh ^{[2
]}

Wang, Hongfang ^{[2
]}

van de Velde, Helgi ^{[2
]}

Jelinek, Tomas ^{[1
,3
,4
]}

Simoes, Catia ^{[1
]}

Prosper, Felipe ^{[1
]}

Miguel, Jesus F. San ^{[1
]}

Alfonso, Ana ^{[1
]}

Bergua, Juan ^{[5
]}

Rodriguez-Veiga, Rebeca ^{[6
]}

Vives, Susana ^{[7
]}

Martinez-Cuadron, David ^{[6
,7
]}

Montesinos, Pau ^{[6
,7
]}

Paiva, Bruno ^{[1
]}

Zabaleta, Aintzane ^{[1
]}

机构：

[1] Clin Univ Navarra, Inst Invest Sanit Navarra, Ctr Invest Med Aplicada, Canc Ctr,CIBER ONC Numbers CB16 12 00369 & CB16 12, Pamplona, Spain

[2] Sanofi R&D, North Amer, Cambridge, MA USA

[3] Univ Ostrava, Univ Hosp Ostrava, Dept Hematooncol, Ostrava, Czech Republic

[4] Univ Ostrava, Fac Med, Ostrava, Czech Republic

[5] Hosp San Pedro Alcantara, Caceres, Spain

[6] Hosp Univ La Fe, Valencia, Spain

[7] Hosp Germans Trias I Pujol, Josep Carreras Res Inst, Inst Catala Oncol Badalona, Badalona, Spain

来源：

BLOOD ADVANCES | 2024年 / 8卷 / 15期

关键词：

OPEN-LABEL; DEXAMETHASONE; DARATUMUMAB; LENALIDOMIDE; EXPRESSION; TREAT;

D O I：

10.1182/bloodadvances.2024013212

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：3875 / 3879

页数：5

共 24 条

[21] How I treat refractory and relapsed acute myeloid leukemia [J].

Thol, Felicitas ;

Doehner, Hartmut ;

Ganser, Arnold .

BLOOD, 2024, 143 (01) :11-20

[22] EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes [J].

van Dongen, J. J. M. ;

Lhermitte, L. ;

Boettcher, S. ;

Almeida, J. ;

van der Velden, V. H. J. ;

Flores-Montero, J. ;

Rawstron, A. ;

Asnafi, V. ;

Lecrevisse, Q. ;

Lucio, P. ;

Mejstrikova, E. ;

Szczepanski, T. ;

Kalina, T. ;

de Tute, R. ;

Brueggemann, M. ;

Sedek, L. ;

Cullen, M. ;

Langerak, A. W. ;

Mendonca, A. ;

Macintyre, E. ;

Martin-Ayuso, M. ;

Hrusak, O. ;

Vidriales, M. B. ;

Orfao, A. .

LEUKEMIA, 2012, 26 (09) :1908-1975

[23] A phase 3 trial of azacitidine versus a semi-intensive fludarabine and cytarabine schedule in older patients with untreated acute myeloid leukemia [J].

Vives, Susana ;

Martinez-Cuadron, David ;

Bergua Burgues, Juan ;

Algarra, Lorenzo ;

Tormo, Mar ;

Martinez-Sanchez, Maria Pilar ;

Serrano, Josefina ;

Herrera, Pilar ;

Ramos, Fernando ;

Salamero, Olga ;

Lavilla, Esperanza ;

Lopez-Lorenzo, Jose L. ;

Gil, Cristina ;

Vidriales, Belen ;

Falantes, Jose F. ;

Serrano, Alfons ;

Labrador, Jorge ;

Sayas, Maria J. ;

Foncillas, Maria A. ;

Amador Barciela, Maria L. ;

Olave, Maria Teresa ;

Colorado, Mercedes ;

Gascon, Adriana ;

Fernandez, Maria a. ;

Simiele, Adriana ;

Perez-Encinas, Manuel M. ;

Rodriguez-Veiga, Rebeca ;

Garcia, Olga ;

Martinez-Lopez, Joaquin ;

Barragan, Eva ;

Paiva, Bruno ;

Sanz, Miguel A. ;

Montesinos, Pau .

CANCER, 2021, 127 (12) :2003-2014

[24] Trispecific antibodies enhance the therapeutic efficacy of tumor-directed T cells through T cell receptor co-stimulation [J].

Wu, Lan ;

Seung, Edward ;

Xu, Ling ;

Rao, Ercole ;

Lord, Dana M. ;

Wei, Ronnie R. ;

Cortez-Retamozo, Virna ;

Ospina, Beatriz ;

Posternak, Valeriya ;

Ulinski, Gregory ;

Piepenhagen, Peter ;

Francesconi, Elisa ;

El-Murr, Nizar ;

Beil, Christian ;

Kirby, Patrick ;

Li, Aiqun ;

Fretland, Jennifer ;

Vicente, Rita ;

Deng, Gejing ;

Dabdoubi, Tarik ;

Cameron, Beatrice ;

Bertrand, Thomas ;

Ferrari, Paul ;

Pouzieux, Stephanie ;

Lemoine, Cendrine ;

Prades, Catherine ;

Park, Anna ;

Qiu, Huawei ;

Song, Zhili ;

Zhang, Bailin ;

Sun, Fangxian ;

Chiron, Marielle ;

Rao, Srinivas ;

Radosevic, Katarina ;

Yang, Zhi-yong ;

Nabel, Gary J. .

NATURE CANCER, 2020, 1 (01) :86-+

← 1 2 3 →